PRDM9 and cancer: We could find no evidence that any of the human orthologues of RIK were differentially activated in cancer cells expressing PRDM9, but the possibility remains that active PRDM9 protein in somatic cells might trigger unscheduled transcriptional activity and/or generate regions with altered chromatin structure which could form unstable chromatin lesions, both of which could be oncogenic in nature.